ReviewBiomolecules2019
Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule.
Review in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 141 citations in OpenAlex.
- Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NADCells · 2026Article
- Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC.EFSA journal. European Food Safety Authority · 2026Article
- Nicotinamide mononucleotide and nicotinamide riboside attenuate cytokine production in human keratinocytes via suppression of p38 Pathway.Molecular biology reports · 2026Article
- Integrated analysis of transcriptome and metabolome reveals the molecular interactions and regulation of muscle flavor precursors in Tengchong Snow chickens and AA broilers.Frontiers in veterinary science · 2026Article
- Exploring the therapeutic potential of β-nicotinamide mononucleotide (NMN) in regulating canine NT-proBNP levels.Journal of advanced veterinary and animal research · 2026Article
- β-Nicotinamide mononucleotide alleviates Alcohol-Induced liver injury in a mouse model through activation of NADHereditas · 2025Article
- Engineering a newly identified alcohol dehydrogenase from Sphingobium Sp. for efficient utilization of nicotinamide cofactors biomimetics.Bioresources and bioprocessing · 2025Article
- NADInternational journal of molecular sciences · 2025Article
- Polydatin and Nicotinamide Prevent Iron Accumulation and Lipid Peroxidation in Cellular Models of Mitochondrial Diseases.Antioxidants (Basel, Switzerland) · 2025Article
- Transcriptome-guided engineering of a native niacin transporter inFrontiers in microbiology · 2025Article
- Nicotinamide mononucleotide alleviates endotoxin-induced acute lung injury by modulating macrophage polarization via the SIRT1/NF-κB pathway.Pharmaceutical biology · 2024Article
- Research advances in the function and anti-aging effects of nicotinamide mononucleotide.Journal of Zhejiang University. Science. B · 2024Review
- Advancements in NMN biotherapy and research updates in the field of digestive system diseases.Journal of translational medicine · 2024Review
- Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide.Nutrients · 2024Review
- Supplementation with NAD+ and its precursors: A rescue of female reproductive diseases.Biochemistry and biophysics reports · 2024Review
- FTO deficiency in older livers exacerbates ferroptosis during ischaemia/reperfusion injury by upregulating ACSL4 and TFRC.Nature communications · 2024Article
- Polydatin and Nicotinamide Rescue the Cellular Phenotype of Mitochondrial Diseases by Mitochondrial Unfolded Protein Response (mtUPR) Activation.Biomolecules · 2024Article
- Article
- Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests.Current research in toxicology · 2024Article
- Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotinamide mononucleotide (NMN) is a nucleotide that is most recognized for its role as an intermediate of nicotinamide adenine dinucleotide (NAD+) biosynthesis. Although the biosynthetic pathway of NMN varies between eukaryote and prokaryote, two pathways are mainly followed in case of eukaryotic human-one is through the salvage pathway using nicotinamide while the other follows phosphorylation of nicotinamide riboside. Due to the unavailability of a suitable transporter, NMN enters inside the mammalian cell in the form of nicotinamide riboside followed by its subsequent conversion to NMN and NAD+. This particular molecule has demonstrated several beneficial pharmacological activities in preclinical studies, which suggest its potential therapeutic use. Mostly mediated by its involvement in NAD+ biosynthesis, the pharmacological activities of NMN include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity. The recent groundbreaking discovery of anti-ageing activities of this chemical moiety has added a valuable essence in the research involving this molecule. This review focuses on the biosynthesis of NMN in mammalian and prokaryotic cells and mechanism of absorption along with the reported pharmacological activities in murine model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.